StockNews.AI
RGEN
StockNews.AI
189 days

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

1. Repligen will report Q4 2024 results on February 20, 2025. 2. Conference call will discuss financials and business updates. 3. The company specializes in bioprocessing technology for drug manufacturing. 4. Repligen operates primarily in the U.S. with global manufacturing sites. 5. Investors are warned about risks in forward-looking statements.

5m saved
Insight
Article

FAQ

Why Neutral?

The earnings report could yield either positive or negative results, lacking clear guidance.

How important is it?

Earnings reports are crucial for stock valuation; however, current data lacks definitive trends.

Why Short Term?

Upcoming financial results will impact RGEN's stock in the immediate future, similar to past earnings events.

Related Companies

RGENCDMOFLEXAMGN
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET February 11, 2025 07:30 ET  | Source: Repligen Corporation WALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2024 financial results on Thursday, February 20, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 6188777.   About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn. This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law. Repligen Contact: Sondra S. NewmanVP, Global Head of Investor Relations(781) 419-1881investors@repligen.com

Related News